Incyte | INCY - Cost Of Sales

Stock Price
101.26
Daily Change
1.17 1.17%
Monthly
0.08%
Yearly
37.77%
Q1 Forecast
98.18

Incyte reported $121.18M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agenus USD 137K 19K Mar/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Exelixis USD 26.48M 7.91M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025